𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis

✍ Scribed by Anastasia Lambrianides; Tabitha Turner-Stokes; Charis Pericleous; Jasmine Ehsanullah; Eva Papadimitraki; Katie Poulton; Yiannis Ioannou; Andrew Lawrie; Ian Mackie; Pojen Chen; David Latchman; David Isenberg; Anisur Rahman; Ian Giles

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
271 KB
Volume
63
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

✦ Synopsis

Objective

To characterize the interaction between procoagulant and/or anticoagulant serine proteases and human monoclonal IgG antiphospholipid antibodies (aPL) and polyclonal IgG derived from patients with the antiphospholipid syndrome (APS).

Methods

Five human monoclonal IgG with small differences in their sequences were tested for binding to protein C, activated protein C, plasmin, factor VIIa (FVIIa), FIX, FIXa, and FXII. Serum levels of antithrombin and anti–activated protein C were compared in 32 patients with APS, 29 patients with systemic lupus erythematosus (SLE), and 22 healthy controls. Purified polyclonal IgG derived from APS patients with elevated levels of serum antithrombin antibodies was also tested for its functional effects on thrombin and antithrombin activity.

Results

Studies of monoclonal antibodies showed that sequence changes in human aPL are important in determining their ability to bind procoagulant and anticoagulant/fibrinolytic serine proteases. Mean IgG antithrombin levels were significantly elevated in patients with APS and in SLE patients with aPL but no APS (SLE/aPL+) compared to healthy controls, but anti–activated protein C levels were not increased in these patients. Moreover, IgG purified from patients with APS displayed higher avidity for thrombin and significantly inhibited antithrombin inactivation of thrombin compared with IgG from SLE/aPL+ patients.

Conclusion

High-avidity antithrombin antibodies, which prevent antithrombin inactivation of thrombin, distinguish patients with APS from SLE/aPL+ patients, and thus may contribute to the pathogenesis of vascular thrombosis in APS.

📜 SIMILAR VOLUMES

Immunoreactivities of polyclonal and mon
Immunoreactivities of polyclonal and monoclonal anti-T and anti-Tn antibodies with human carcinoma cells, grown in vitro and in a xenograft model
✍ Dody Avichezer; Georg F. Springer; Bilha Schechter; Ruth Arnon 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 191 KB 👁 2 views

Human polyclonal, monospecific anti-T and -Tn antibodies were found to be reactive in ELISA tests with human ovarian (IGROV-1, OVCAR-3 and SKOV-3), breast (SKBr-3 and T47D)- and oral (KB)-carcinoma cell lines, but less so or non-reactive with normal epithelia and fibroblasts. The direct binding radi

Investigation and molecular mimicry of t
Investigation and molecular mimicry of the antigen involved in the interaction between the monoclonal antibody 5D10 and the human breast cancer cell line MCF-7
✍ Caroline Vandevyver; Stéphane Canarelli; Claudia Bossen; Igor Fisch; Kris Motman 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 328 KB

## Abstract Monoclonal antibody (mAb) 5D10 is directed against the human breast cancer cell line MCF‐7. Biochemical characterization of the antibody epitope was attempted and revealed a complex, most likely carbohydrate‐linked nature, which prevented isolation and further studies of the interaction

Erratum: Immunoreactivities of polyclona
Erratum: Immunoreactivities of polyclonal and monoclonal anti-T and anti-Tn antibodies with human carcinoma cells, grown in vivo and in a xenograft model. Int. J. Cancer, 72, 119-127 (1997)
✍ Dody Avichezer; George F. Springer; Bilha Schechter; Ruth Arnon 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 9 KB 👁 2 views

The following information was published incorrectly in the article by Avichezer et al. 1. On page 120, line 9, left-hand column: monoclonal anti-Tn antibody should read Ca 3783, not 3782, the latter has anti-T specificity. 2. On page 123, Table II, footnote 2 should read as follows: The data in bra